drugset / Trial / NCT01971489

Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

NCT01971489

Phase 1 Withdrawn Roswell Park Cancer Institute
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and the best doses of buparlisib, gemcitabine hydrochloride, and cisplatin in treating patients with solid tumors that have spread to other places in the body. Buparlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving buparlisib, gemcitabine hydrochloride, and cisplatin may be a better treatment for solid tumors.

Timeline

Start
2015-09
Primary completion
2016-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Buparlisib Small molecule Oral
Subject Cisplatin Other / unclassified Intravenous
Subject Gemcitabine Small molecule Intravenous